EPITRACKER PULMONARY DISEASE
& THERAPEUTICS PROGRAM
At Epitracker, we are searching for new treatments for cytokine storms related to pulmonary infections (such as COVID-19), chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis . Our pulmonary disease therapeutics program has resulted in the discovery of several promising molecules, including ETI-070 and ETI-059.
ETI-070 to Stem Pulmonary Inflammation & Cytokine Storms
COVID-19 and other lung infections can cause over-reactive immune systems, resulting in extensive edema and pulmonary cell damage. Cytokines are pro-inflammatory molecules that are released during this process, also called a 'cytokine storm'.
ETI-070 is a lipid in the fatty acid metabolism pathway that is demonstrating promise as a novel therapeutic to stem exacerbated pulmonary inflammation (cytokine storms) during lung infections and chronic obstructive pulmonary disease.
ETI-070 has demonstrated dose-dependent anti-inflammatory activity in a human cell system mimicking Th1 type lung inflammation. ETI-070 significantly reduced interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11) , interleukin (IL)-1, matrix metalloproteinase (MMP)-1, MMP-9, and plasminogen activation inhibitor (PAI)-I in human bronchial epithelial cells.
As part of a Phase II Small Business Innovation Research (SBIR) project set to be funded by the Office of Naval Research, Epitracker will be investigating the pharmacokinetics and activities of ETI-070 to better understand its potential as a means to prevent or treat inflammation, including cytokine storms during pulmonary infections.
ETI-070 is a lipid in the fatty acid metabolism pathway that is demonstrating promise as a novel therapeutic to stem exacerbated pulmonary inflammation (cytokine storms) during lung infections and chronic obstructive pulmonary disease.
ETI-070 has demonstrated dose-dependent anti-inflammatory activity in a human cell system mimicking Th1 type lung inflammation. ETI-070 significantly reduced interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11) , interleukin (IL)-1, matrix metalloproteinase (MMP)-1, MMP-9, and plasminogen activation inhibitor (PAI)-I in human bronchial epithelial cells.
As part of a Phase II Small Business Innovation Research (SBIR) project set to be funded by the Office of Naval Research, Epitracker will be investigating the pharmacokinetics and activities of ETI-070 to better understand its potential as a means to prevent or treat inflammation, including cytokine storms during pulmonary infections.
ETI-059 to Treat Idiopathic Pulmonary Fibrosis
Pulmonary fibrosis is a chronic and progressive condition involving inflammation and fibrosis in the lung caused by environmental or occupational exposures, underlying autoimmune disease, or, most commonly, unknown factors (called idiopathic pulmonary fibrosis, or IPF). Pulmonary fibrosis is characterized by an increase in fibrotic tissue in the lung, making it difficult for oxygen to enter the body, resulting in shortness of breath and eventual loss of pulmonary function.
This condition is a frequent endpoint in many lung disorders, such as lung infections and interstitial lung disease. The prevalence of IPF is increasing, resulting in increased rates in hospital admissions and deaths. Today, an estimated 1 in 200 adults over 60 years old in the U.S. has pulmonary fibrosis. 50,000 new cases are diagnosed annually, and every year, 40,000 Americans die from PF. Without effective treatments, IPF has a low survival rate of 39% at 5 years.
ETI-059 is a lipid-based analog being advanced by Epitracker as a potential therapeutic for pulmonary fibrosis.
ETI-059 has demonstrated dose-dependent anti-inflammatory activity in human cell systems mimicking pulmonary inflammation and fibrosis. In these primary human cell systems, ETI-059 significantly reduced fibroblast proliferation, plasminogen activation inhibitor (PAI)-I, and Collagen I.
As part of a new project funded by the Peer Reviewed Medical Research Program within the Congressionally Directed Medical Research Programs, Epitracker will be advancing ETI-059 or related analogs as novel prescription therapeutics to treat pulmonary fibrosis.
This condition is a frequent endpoint in many lung disorders, such as lung infections and interstitial lung disease. The prevalence of IPF is increasing, resulting in increased rates in hospital admissions and deaths. Today, an estimated 1 in 200 adults over 60 years old in the U.S. has pulmonary fibrosis. 50,000 new cases are diagnosed annually, and every year, 40,000 Americans die from PF. Without effective treatments, IPF has a low survival rate of 39% at 5 years.
ETI-059 is a lipid-based analog being advanced by Epitracker as a potential therapeutic for pulmonary fibrosis.
ETI-059 has demonstrated dose-dependent anti-inflammatory activity in human cell systems mimicking pulmonary inflammation and fibrosis. In these primary human cell systems, ETI-059 significantly reduced fibroblast proliferation, plasminogen activation inhibitor (PAI)-I, and Collagen I.
As part of a new project funded by the Peer Reviewed Medical Research Program within the Congressionally Directed Medical Research Programs, Epitracker will be advancing ETI-059 or related analogs as novel prescription therapeutics to treat pulmonary fibrosis.